| Similar Articles |
|---|
 |
The Motley Fool
April 1, 2008
Brian Lawler |
VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market.   |
The Motley Fool
September 16, 2011
Brian Orelli |
A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
The Motley Fool
September 9, 2009
Brian Orelli |
Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa |
The Motley Fool
September 21, 2010
Brian Orelli |
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. |
The Motley Fool
July 14, 2010
Luke Timmerman |
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug |
The Motley Fool
May 27, 2008
Brian Orelli |
Livin' la Vivus Loca Irrational Exuberance for Vivus' Lead Drug Candidate? |
The Motley Fool
July 16, 2010
Luke Timmerman |
Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics. |
The Motley Fool
May 25, 2011
Brian Orelli |
Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 21, 2011
Brian Orelli |
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. |
The Motley Fool
May 4, 2011
Brian Orelli |
VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
January 9, 2012
Brian Orelli |
Don't Believe This Company's Warning VIVUS' news is great news. |
The Motley Fool
May 3, 2007
Mike Havrilla |
Heads Up, Biotech Investors: Chapter 3 Time your stocks, not the market. Savient... VISICU... VIVUS... Cortex... |
The Motley Fool
January 31, 2011
Brian Orelli |
5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list. |
The Motley Fool
December 27, 2006
Brian Lawler |
Bradley's Mediocre Drug Approval With the FDA's approval of Bradley's Elestrin, shares were up over 10% upon approval last week. |
The Motley Fool
July 16, 2010
Brian Orelli |
Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa. |
The Motley Fool
September 2, 2010
Luke Timmerman |
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
The Motley Fool
July 16, 2010
Tom Hughes |
Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
The Motley Fool
September 2, 2010
Brian Orelli |
Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them. |
The Motley Fool
April 5, 2011
Brian Orelli |
Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Chemistry World
September 17, 2010
Andrew Turley |
Obesity drugs strive for US approval Could 2010 yet be the year of the obesity drug? At first glance the signs are promising. Regulators in the US will soon decide whether to allow three new contenders onto this attractive market. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
December 12, 2008
Brian Orelli |
The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success? |
The Motley Fool
February 14, 2011
Brian Orelli |
This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue. |
Chemistry World
July 18, 2012
Andrew Turley |
Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise. |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
The Motley Fool
December 22, 2011
Brian Orelli |
VIVUS' Obese Pink Elephant Qnexa data can't be ignored. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
October 25, 2010
Brian Orelli |
Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
February 1, 2011
Brian Orelli |
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. |
The Motley Fool
September 16, 2010
Brian Orelli |
Abbott's Product Line May Get Thinner Not that it needs the obesity drug. |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
The Motley Fool
December 3, 2010
Brian Orelli |
Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel. |
The Motley Fool
March 17, 2011
Brian Orelli |
Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
November 23, 2009
Brian Orelli |
The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
December 31, 2009
Brian Orelli |
2010 FDA Decisions to Watch It's a pivotal year for these drugmakers. |
The Motley Fool
January 4, 2012
Brian Orelli |
This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval. |
